Patents Examined by James Joseph Graber
-
Patent number: 11975043Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.Type: GrantFiled: October 13, 2022Date of Patent: May 7, 2024Assignee: Genzyme CorporationInventors: Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
-
Patent number: 11976301Abstract: The present invention provides a method for producing megakaryocytes that have an increased capacity to produce platelets, the method comprising a step of culturing, under conditions that cause the death of cells that do not express a gene that is specifically expressed by megakaryocytes, cells that have the capacity to differentiate into megakaryocytes.Type: GrantFiled: March 22, 2021Date of Patent: May 7, 2024Assignees: Megakaryon Corporation, Kyoto UniversityInventors: Takeaki Dohda, Sachiko Kobayashi, Koji Eto, Hiroshi Endo, Sou Nakamura
-
Patent number: 11939594Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.Type: GrantFiled: March 14, 2018Date of Patent: March 26, 2024Assignee: Seattle Children's HospitalInventors: David J. Rawlings, Richard James, Shaun W. Jackson, Iram Khan, King Hung, Andrew M. Scharenberg
-
Patent number: 11931427Abstract: The present inventions relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.Type: GrantFiled: October 30, 2020Date of Patent: March 19, 2024Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Josephine Juettner, Dasha Nelidova, Botond Roska
-
Patent number: 11911440Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.Type: GrantFiled: November 10, 2022Date of Patent: February 27, 2024Assignee: Genzyme CorporationInventors: Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
-
Patent number: 11866480Abstract: This invention relates to vectors for delivery of human leukocyte antigen G to the eye and/or to cornea explants and methods of using the same for treatment and/or prevention of corneal transplant rejection and other disorders associated with an immune response and/or vascularization.Type: GrantFiled: July 26, 2017Date of Patent: January 9, 2024Assignees: The University of North Carolina at Chapel Hill, North Carolina State UniversityInventors: Matthew Louis Hirsch, Brian Christopher Gilger
-
Patent number: 11859216Abstract: Bacillus agaradhaerens strain WDG185 expresses an inulosucrase that efficiently synthesizes a broad range of IOS with a GF range of GF3-GF30. The isolated and/or purified inulosucrase, recombinantly engineered variants thereof, active fragments thereof, synthetic nucleic acids encoding the inulosucrase, its variants, or its active fragments, host cells comprising the synthetic nucleic acids, and compositions comprising the inulosucrase are provided. Methods of using the compositions include the manufacture of inulooligosaccharides.Type: GrantFiled: September 17, 2020Date of Patent: January 2, 2024Assignee: Danisco US Inc.Inventors: Slavko Kralj, Marc Kolkman, Chris Leeflang, Johannes G. De Nobel, Arjen Hoekstra, Veli Alkan
-
Patent number: 11851676Abstract: Human Neural precursor cells (hNPCs)/cell lines derived from human pluripotent stem cells have been stably transduced with inducible lentiviral constructs for knockdown of STIM1 thereby changing their gene expression. The said Human Neural precursor cells (hNPCs)/cell lines has selectively inducible knockdown of STIM1 via stable transduction of lentiviral shRNA vector followed by Doxycycline treatment. Human Neural precursor cells (hNPCs)/cell lines with stable knockdown STIM1 exhibits attenuated SOCE with downregulation of genes associated with cell proliferation and upregulation of genes for neural differentiation.Type: GrantFiled: April 17, 2019Date of Patent: December 26, 2023Assignee: NATIONAL CENTRE FOR BIOLOGICAL SCIENCESInventors: Renjitha Gopurappilly, Gaiti Hasan, Bipan Kumar Deb
-
Patent number: 11813317Abstract: Provided is a method for preventing or treating a metabolic disorder, including administering to a subject a therapeutically effective amount of TRABID protein or a functionally related variant thereof, or a nucleic acid encoding TRABID protein or a functionally related variant thereof. Also provided is a method for reducing fat accumulation through TRABID-induced deubiquitination to promote autophagy activity and lipid metabolism.Type: GrantFiled: December 2, 2021Date of Patent: November 14, 2023Assignees: Academia Sinica, National Yang Ming Chiao Tung UniversityInventors: Ruey-Hwa Chen, Yu-Hsuan Chen, Tzu-Yu Huang, Wen-Hsin Li, Ting-Fen Tsai, Zhao-Qing Shen
-
Patent number: 11781142Abstract: Aspects of the disclosure relate to methods and compositions for treating pancreatic cancer (e.g., islet cell tumors). In some aspects, adeno-associated virus (AAV) may be used to deliver an interfering RNA that targets thymidylate synthase (TS).Type: GrantFiled: November 3, 2017Date of Patent: October 10, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Maria Zajac-Kaye, Kyungah Maeng
-
Patent number: 11773368Abstract: A problem of this invention it to provide a method for differentiate a primordial germ cell into a functional GV stage oocyte by in vitro culture. This invention relates to a method for differentiating a primordial germ cell into a functional GV stage oocyte by in vitro culture, comprising: (a) a step of producing a secondary follicle by culturing the primordial germ cell and supporting cells adjacent to the primordial germ cells under conditions that eliminate the effects of estrogen or a factor having a similar function to estrogen; (b) a step of partially dissociating cells between a granulosa cell layer and a thecal cell layer, wherein an oocyte, the granulosa cell layer, and the thecal cell layer constitute the produced secondary follicle; and (c) a step of differentiating the oocyte into a functional GV stage oocyte by culturing the oocyte, the granulosa cell layer, and the thecal cell layer that constitute the secondary follicle in a medium containing a high-molecular-weight compound.Type: GrantFiled: September 16, 2016Date of Patent: October 3, 2023Assignees: NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, TOKYO UNIVERSITY OF AGRICULTURE EDUCATIONAL CORPORATEDInventors: Yayoi Obata, Yuji Hirao, Katsuhiko Hayashi
-
Patent number: 11752181Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).Type: GrantFiled: May 4, 2018Date of Patent: September 12, 2023Assignee: VOYAGER THERAPEUTICS, INC.Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
-
Patent number: 11732240Abstract: The present invention relates to a composition for inducing direct conversion from a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell (iHSC), a hepatocyte, and a cholangiocyte, and a method of direct conversion of a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell, a hepatocyte, and a cholangiocyte.Type: GrantFiled: July 27, 2017Date of Patent: August 22, 2023Assignee: UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)Inventors: Jeong Beom Kim, Myung Rae Park, Man Sze Wong
-
Patent number: 11708561Abstract: Compositions of genetically modified beta-like cells are encompassed. Also encompassed are methods of treatment of type 1 diabetes using these compositions or compositions that inhibit the function of the identified genes.Type: GrantFiled: August 16, 2019Date of Patent: July 25, 2023Assignee: Joslin Diabetes CenterInventors: Stephan Kissler, Peng Yi
-
Patent number: 11679133Abstract: The present invention relates to compositions and methods comprising cell surface markers for pluripotent-derived cells, in particular, pancreatic endoderm-type cells, derived from pluripotent stem cells.Type: GrantFiled: November 28, 2016Date of Patent: June 20, 2023Assignees: Kadimastem Ltd., Yeda Research and Development Co. Ltd.Inventors: Kfir Molakandov, Neta Lavon, Avital Beck, Michel Revel, Ofer Elhanani, Yoav Soen, Michael Walker, Arik Hasson
-
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
Patent number: 11660353Abstract: The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.Type: GrantFiled: April 26, 2019Date of Patent: May 30, 2023Assignee: Decibel Therapeutics, Inc.Inventors: Joseph Burns, Kathryn Ellis, Adam Palermo, Martin Schwander, Jonathon Whitton -
Patent number: 11628226Abstract: Disclosed are novel gene therapy constructs containing both HEXA and HEXB genes to treat GM2 gangliosidoses, including Sandhoff disease and Tay-Sach's disease. Also described are co-treatments using chaperone and anti-inflammatory agents to enhance the effects of gene therapy.Type: GrantFiled: May 20, 2021Date of Patent: April 18, 2023Assignees: Queen's University at Kingston, Kingston Health Sciences CentreInventor: Jagdeep Singh Walia
-
Patent number: 11608365Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.Type: GrantFiled: June 8, 2021Date of Patent: March 21, 2023Assignee: Friedrich Miescher Institute for Biomedical ResearchInventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
-
Patent number: 11591618Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.Type: GrantFiled: April 6, 2021Date of Patent: February 28, 2023Assignee: Friedrich Miescher Institute for BioMedical ResearchInventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
-
Patent number: 11583564Abstract: Methods and materials for intrathecal delivery of recombinant Adeno-associated virus 9 (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) are provided. Use of the methods and materials is contemplated, for example, for the treatment of Rett syndrome.Type: GrantFiled: November 17, 2017Date of Patent: February 21, 2023Assignees: NATIONWIDE CHILDREN'S HOSPITAL, INC., OHIO STATE INNOVATION FOUNDATIONInventors: Brian K. Kaspar, Kevin Foust